

1 **Masseter Muscle Volume and Its Association with Sarcopenia and Muscle**  
2 **Determinants with Insights from ACTN3 Polymorphism in Older Japanese Adults:**  
3 **the Bunkyo Health Study**

4  
5 Abulaiti Abudurezake <sup>1</sup>, Saori Kakehi <sup>1,2</sup>, Futaba Umemura <sup>2</sup>, Hideyoshi Kaga <sup>3</sup>, Yuki  
6 Someya <sup>4</sup>, Hiroki Tabata <sup>1</sup>, Yasuyo Yoshizawa <sup>5</sup>, Hitoshi Naito <sup>3</sup>, Tsubasa Tajima <sup>3</sup>, Naoaki  
7 Ito <sup>3</sup>, Hikaru Otsuka <sup>2</sup>, Huicong Shi <sup>2</sup>, Mari Sugimoto <sup>2</sup>, Shota Sakamoto <sup>2</sup>, Yukiko Muroga  
8 <sup>2</sup>, Hidetaka Wakabayashi <sup>6</sup>, Ryuzo Kawamori <sup>1 2 3</sup>, Hirotaka Watada <sup>1,3</sup>, Yoshifumi Tamura  
9 <sup>1,2,3,5,7</sup>

10

11 <sup>1</sup>Sportology Center, Graduate School of Medicine, Juntendo University.

12 <sup>2</sup>Department of Sports Medicine and Sportology, Graduate School of Medicine, Juntendo  
13 University.

14 <sup>3</sup>Metabolism and Endocrinology, Graduate School of Medicine, Juntendo University.

15 <sup>4</sup>Graduate School of Health and Sports Science, Juntendo University.

16 <sup>5</sup>Center for Healthy Life Expectancy, Graduate School of Medicine, Juntendo University.

17 <sup>6</sup>Department of Rehabilitation Medicine, Tokyo Women's Medical University.

18 <sup>7</sup>Faculty of International Liberal Arts, Juntendo University.

19

20 **Short title:** Masseter Muscle Volume in Older Japanese Adults

21

22 **Word count:**

23 Abstract: 247 words

24 Text: 3074 words

25 **Number of figures and tables: 5**

26

27 **Corresponding author:**

28 Saori Kakehi, PhD

29 Sportology Center, Graduate School of Medicine, Juntendo University

30 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan

31 Tel: +81-3-3813-3111

32 Fax: +81-3-3813-5996

33 E-mail: [skakei@juntendo.ac.jp](mailto:skakei@juntendo.ac.jp)

34

35 **Abstract**

36

37 **Aim**

38 Sarcopenia has been associated with a decrease in masseter muscle (MM) thickness in  
39 high-risk older populations. However, the relationship to sarcopenia and determinants of  
40 MM volume (MMV) in the general older population remain unclear.

41

42 **Method**

43 In a cross-sectional study of 1484 older adults of Tokyo, we evaluated MMV using 3D  
44 MRI scanning, appendicular skeletal muscle mass (ASMM), handgrip strength, dietary  
45 intake, smoking, insulin-like growth factor 1 (IGF-1) levels, and the ACTN3 R577X  
46 polymorphism. Participants were divided into quintiles based on MMV (Q1-5).

47

48 **Results**

49 Our study of participants with a mean age of  $73.0 \pm 5.3$  years, MMV (Men:  $35.3 \pm 7.8$  ml,  
50 Women:  $25.0 \pm 5.1$  ml) was significantly larger in men than in women. A significant  
51 association between MMV and sarcopenia was observed, with the lowest quintile (Q1)  
52 showing a higher risk compared to the highest quintile (Q5) in both sexes. Body mass  
53 index (BMI) and age were independent determinants of ASMM in both sexes, while BMI,  
54 but interestingly not age, was a determinant of MMV. Moreover, IGF-1 was positively  
55 correlated with MMV in both sexes; smoking negatively correlated with MMV in women.  
56 The ACTN3 577X polymorphism was associated with only smaller MMV in men.

57

58 **Conclusion**

59 Low MMV increased the risk of sarcopenia, particularly in men. BMI and age strongly  
60 influenced ASMM, while MMV was only weakly associated with BMI and not with age.  
61 Notably, the IGF-1 level was positively correlated to only MMV, and the ACTN3  
62 genotype was linked to reduced only MMV in men.

63

64

65 **Key words**

66 Sarcopenia, masseter muscle volume, general older population, ACTN3 577XX genotype,  
67 insulin-like growth factor 1

68 **Introduction**

69

70 The rise in the number of older individuals requiring care is a grave issue in aging  
71 societies(1). One potential solution to this problem lies in preventative measures that  
72 reduce the risk of needing care. Sarcopenia, a condition characterized by diminished  
73 muscle mass, reduced muscle strength, and compromised physical function(2, 3),  
74 contributes significantly to the increased risk of mortality and the need for care(4, 5).  
75 Thus, it is presumed that the prevention of sarcopenia plays a pivotal role in mitigating  
76 care requirements.

77         Several risk factors have been associated with an increased risk of sarcopenia,  
78 including aging(6), reduced BMI(7), decreased physical activity(8), and cerebrovascular  
79 disorders(9). Two previous studies highlighted the relationship between masseter muscle  
80 (MM) thickness and sarcopenia (10, 11). In these studies, a mere 1-mm increase in MM  
81 thickness, as measured by ultrasound, significantly decreased the risk of sarcopenia by  
82 ~45% and ~57% in older patients hospitalized for hip fractures and those in nursing  
83 homes, respectively. In addition, MM thickness was significantly associated with skeletal  
84 mass index (SMI) in community-dwelling older people(12). Given these findings, it is  
85 reasonable to expect that decreased MM volume (MMV) may also be associated with  
86 sarcopenia in the general older population. However, the potential association between  
87 MMV and formally diagnosed sarcopenia, as defined by the Asian Working Group for  
88 Sarcopenia (AWGS) 2019 (3), in this population remains unexplored. Another issue is  
89 that the aforementioned studies measured muscle size using ultrasound, which is not the  
90 most accurate method(13). CT or MRI scans are superior because they provide detailed

91 three-dimensional images that enable more precise measurement of muscle volume. In  
92 particular, although CT and MRI scans of the head have been performed in older people,  
93 MM has not been analyzed at all, and it would be clinically useful to identify standard  
94 MMV values and risk prediction thresholds.

95         Even if an association is observed between MMV and sarcopenia, the  
96 determinants of each may be different. It is rare for MM to contract in relation to physical  
97 activity or to exert maximal muscle force(14, 15), and therefore it differs from skeletal  
98 muscles of the extremities, which are active during physical activity. Therefore,  
99 comparing the determinants of appendicular skeletal muscle mass (ASMM) and MMV  
100 may provide important insights into why MMV is associated with sarcopenia, and may  
101 yield a deeper understanding of the mechanisms of muscle mass regulation.

102         Genetic factors are determinants of skeletal muscle mass and function(16-19),  
103 and one of the most extensively studied genes in this context is the  $\alpha$ -actinin-3 gene. The  
104 protein  $\alpha$ -actinin-3, coded by *ACTN3*, forms part of the Z-line of muscle fibers(20) and is  
105 specifically expressed only in fast-twitch skeletal muscle fibers(14). Notably,  
106 homozygosity for a common nonsense polymorphism (R577X) in the *ACTN3* gene results  
107 in a complete deficiency of  $\alpha$ -actinin-3, and in animal models, the lack of actn3 leads to  
108 a reduction in both muscle mass, mainly type II fibers, and muscle strength(21). Indeed,  
109 the *ACTN3* 577XX  $\alpha$ -actinin-3 null genotype is significantly underrepresented in elite  
110 sprint athletes(22), and it increases the risk of sarcopenia in older people (19, 23).  
111 However, it remains unclear whether the *ACTN3* 577XX null genotype is associated with  
112 reduced MMV.

113         Against this background, our study aimed to clarify the relationship between

114 MMV (determined through 3D reconstruction of MRI images) and sarcopenia in older  
115 Japanese people. Furthermore, we compared the determinants of MMV and ASMM,  
116 including genetic polymorphisms of *ACTN3*.

## 117 **Research Design and Methods**

118

### 119 **Study Design and Participants**

120 This cross-sectional study used baseline data from the Bunkyo Health Study(1). Briefly,  
121 in this study, we recruited individuals aged between 65–84 years living in Bunkyo-ku, an  
122 urban area in Tokyo, Japan. The Bunkyo Health Study registry initially enrolled 1629  
123 individuals. From this cohort, we excluded 64 participants who either lacked head MRI  
124 data or image slices that included the masticatory muscles. Additionally, among the  
125 remaining 1565 participants, 66 diagnosed with cerebrovascular disorders and 15 with  
126 unavailable data (body composition [n = 2], physical function [n = 3], genetic type [n =  
127 7]) were also excluded from the study. Consequently, the final sample for this analysis  
128 comprised 1484 participants (603 men, 881 women) (Figure S1). All participants  
129 completed the examinations at the Sportology Center from October 15, 2015, to October  
130 1, 2018. The study protocol was approved by the ethics committee of Juntendo University  
131 in November 2015 (Nos. 2015078, 2016138, 2016131, 2017121, and 2019085). This  
132 study was carried out in accordance with the principles outlined in the Declaration of  
133 Helsinki. All participants gave written informed consent and were informed that they had  
134 the right to withdraw from the trial at any time.

135

### 136 **3D Assessment of MMV**

137 Total MMV was measured by selecting and extracting the data captured by MRI with a  
138 3D medical image analysis system, and reconstructing these data in 3D (24). MRI was  
139 performed in the supine position with the occlusion relaxed. All head MRI data (2-mm-



140 wide T2-weighted images taken with a 0.3 T MRI, Hitachi, Ltd.) were imported into the  
141 workstation software application, AZE Medical Image Processor (AZE Virtual Place,  
142 Canon Medical Co., Ltd.). For each slice, the masticatory muscles were selected and  
143 extracted using a semi-automatic function (Figure S2). The MM was then reconstructed  
144 using the contour trace function. We performed color mapping to ensure that the entire  
145 MM was visible, and the volume was measured using the 3D volumetry function (Figure  
146 S2, 3). We used the mean value of the left and right MMVs. A.A. measured all MMVs,  
147 and the intraclass correlation coefficient and its 95% confidence interval (CI) were 0.944  
148 and 0.989–0.997, respectively.

149

#### 150 **Body composition measurements**

151 ASMM was evaluated with bioelectrical impedance analysis (InBody770, InBody Japan  
152 Inc., Tokyo, Japan), and the SMI was calculated (ASMM/height<sup>2</sup>).

153

#### 154 **Genotyping**

155 Genomic DNA was isolated from whole blood using the standard method (RNeasy Blood  
156 and Tissue DNA Extraction Kit, QIAGEN, Minneapolis, MN, USA). All participants  
157 were genotyped for the ACTN3 R577X (rs1815739) polymorphism using the Infinium  
158 Asian Screening Array-24 v1.0 BeadChip (Illumina, San Diego, CA, USA).

159

#### 160 **Other measurements**

161 Handgrip strength (HGS) was measured using a handgrip dynamometer (T.K.K. 5401,  
162 Takei Scientific Instruments, Niigata, Japan) with the arm held to the side of the body.

163 Physical activity level was evaluated using the International Physical Activity  
164 Questionnaire, which assesses different types of physical activity, such as walking and  
165 both moderate- and high-intensity activities(25). As part of the survey on dietary history,  
166 participants completed the brief diet history questionnaire (BDHQ)(26). Based on  
167 responses to the question about smoking, cumulative cigarette consumption was  
168 expressed as the Brinkman index (cigarette consumption per day multiplied by the  
169 number of years smoking)(27). Insulin-like growth factor 1 (IGF-1) levels were measured  
170 in blood samples collected from participants after an overnight fast.

171

### 172 **Definition of sarcopenia**

173 Sarcopenia was defined as weak HGS (<28 kg for men and <18 kg for women) and low  
174 ASMM (<7.0 kg/m<sup>2</sup> for men and <5.7 kg/m<sup>2</sup> for women) based on the definition of the  
175 AWGS 2019 (3).

176

### 177 **Statistical analyses**

178 All statistical calculations were performed using IBM SPSS Statistics for Windows  
179 version 25 (IBM, Armonk, NY). Data are presented as means  $\pm$  SD or number (%).  
180 Differences between sexes were determined using Student's t-test for continuous variables  
181 and the  $\chi^2$  test for non-continuous variables (Table 1). Participants were divided into  
182 quintiles based on the MMV for each sex (quintiles 1-5: Q1-5). Differences in means and  
183 proportions were evaluated using ANOVA and the  $\chi^2$  test (Table 2). Differences in  
184 characteristics between genotypes (Table 4) were compared using ANOVA and the  $\chi^2$  test.  
185 Adjustments for multiple comparisons were performed using post hoc Bonferroni

186 correction. Logistic regression was used to estimate odds ratios (ORs) and 95%  
187 confidence intervals (CIs) for the prevalence of each outcome in each group, compared  
188 with the reference group. Multiple linear regression was used to examine factors affecting  
189 MMV or ASMM in each group. Potential confounders were based on previous reports  
190 that have identified factors such as BMI, physical activity level, protein intake, diabetes,  
191 smoking, and IGF-1 as being associated with muscle mass or muscle strength(7, 8, 28),  
192 these factors were included as confounders in our analysis. All statistical tests were two-  
193 sided with a 5% significant level.

194 **Results**

195

196 **Characteristics of study participants**

197 Characteristics of the study participants are shown in Table 1. Of 1,484 participants  
198 (average age  $73.0 \pm 5.3$  years), 603 were men (average age  $72.9 \pm 5.3$  years) and 881 were  
199 women (average age  $73.0 \pm 5.4$  years). The MMV and SMI were about 1.4 and 1.3 times  
200 greater in men than in women, respectively, indicating a significant difference in both  
201 cases. HGS was 1.5 times greater in men than in women, also a significant difference.  
202 The prevalence of diabetes was significantly higher in men at 16.5% compared to women  
203 at 7.8%. The prevalence of sarcopenia was comparable between men and women, at  
204 12.4% in men and 11.7% in women.

205

206 **Association between MMV and various body composition indices**

207 MMV was divided into quintiles and clinical features were compared (Table 2). In men,  
208 Q1, representing the lowest MMV, was associated with the lowest values among the  
209 groups for all clinical features other than age and physical activity, and was associated  
210 with the highest proportions of participants with low SMI, low HGS, and sarcopenia.  
211 Compared to Q1, there were significant differences between groups in terms of height  
212 (against Q3, 4, 5), weight (against Q4, 5), BMI (against Q5), ASMM (against Q3, 4, 5),  
213 SMI (against Q3, 4, 5), HGS (against Q2, 3, 4, 5), and IGF-1 (for Q3, 4, 5). Similar trends  
214 were observed in women. Compared to Q1, there were significant differences between  
215 groups in weight (against Q2, 3, 5), BMI (against Q5), ASMM (against Q2, 3, 4, 5), SMI  
216 (against Q2, 3, 4, 5), HGS (against Q3, 4, 5), and IGF-1 (for Q3, 5).

217

### 218 **Relationship between MMV and sarcopenia**

219 To clarify whether decreased MMV was independently associated with the prevalence of  
220 sarcopenia, we conducted a logistic regression analysis (Table 3). After adjusting for age  
221 and BMI in Model 1, Q1 was associated with a significantly higher OR for the prevalence  
222 of sarcopenia compared to Q5 in both men and women (men, OR: 6.624, 95% CI: 2.175–  
223 20.178,  $p < 0.001$ ; women, OR: 2.178, 95% CI: 1.044–4.546,  $p = 0.038$ ), and the OR for  
224 Q2 in men was also significantly different relative to Q5 (OR: 3.440, 95% CI: 1.078–  
225 10.976,  $p = 0.037$ ). In model 2, which adjusted for physical activity, protein intake,  
226 Brinkman index, and IGF-1, the ORs of Q1 in men (OR: 6.573, 95% CI: 2.101–20.559,  
227  $p = 0.001$ ) and in women (OR: 2.192, 95% CI: 1.033–4.652,  $p = 0.041$ ) were still  
228 significant compared to Q5.

229

### 230 **Relationship between ACTN3 R577X polymorphism and MMV**

231 Next, we examined the association between MMV or ASMM and ACTN3 577XX  
232 genotypes. The samples exhibited no deviation from the Hardy-Weinberg equilibrium. As  
233 shown in Table 4, in men with the ACTN3 577XX genotype, MMV was significantly  
234 lower compared to other genotypes, but ASMM was similar across genotypes. In contrast,  
235 no association was found between genotype and either MMV or ASMM in women.

236

### 237 **Multiple regression model of factors predicting MMV or ASMM**

238 We next performed a multiple regression analysis to identify the independent  
239 determinants of MMV and ASMM (Table 5). In the total variance explained by the model,

240  $R^2$  was much lower in MMV than in ASMM in both sexes. This difference was mainly  
241 due to the much more significant standardized  $\beta$  values of BMI and age for ASMM than  
242 for MMV in both sexes. BMI was positively correlated (men,  $\beta = 0.618$ ; women,  $\beta =$   
243  $0.600$ ) and age was negatively correlated (men,  $\beta = -0.296$ ; women,  $\beta = 0.246$ ) with  
244 ASMM in both sexes, while BMI (men,  $\beta = -0.168$ ; women,  $\beta = -0.110$ ), but interestingly  
245 not age, was positively correlated with MMV. In addition, IGF-1 was positively correlated  
246 with MMV in both sexes, while smoking was negatively correlated with MMV in women.  
247 The ACTN3 577X polymorphism in men, but not in women, was associated with smaller  
248 MMV, which was consistent with the analysis in Table 4.

249 **Discussion**

250

251 In the present study, we measured MMV in community-dwelling older people in Japan  
252 and investigated its relationship with sarcopenia. Furthermore, we compared  
253 determinants of MMV and ASMM, including genetic polymorphisms of *ACTN3*. Our  
254 findings indicated that men in the group with the lowest MMV had a 6.9-fold increased  
255 risk of sarcopenia, while women had a 2.1-fold increased risk, compared to those in the  
256 group with the highest MMV. Multiple regression analysis revealed that both BMI and  
257 age were independent determinants of ASMM in both sexes. However, for MMV, the  
258 *ACTN3* genotype and IGF-1 were independent determinants in men, whereas smoking  
259 and IGF-1 emerged as significant factors in women.

260 The present study revealed an association between MMV and sarcopenia, which  
261 is consistent with the findings of prior cohort studies(10, 11) that utilized ultrasound to  
262 measure MMT. Importantly, our participants were community-dwelling individuals who  
263 were over a decade younger (73 years old) compared to those in previous studies (86 or  
264 84.7 years old), and were either hospitalized for hip fractures or who resided in nursing  
265 homes(10, 11). In this large-scale study, we found a substantial rise in the OR of  
266 sarcopenia in men within the two lowest quintiles of MMV (Q1 and Q2) when compared  
267 to the group with the largest MMV (Q5). Conversely, in women, a significant increase in  
268 OR was only observed in Q1, although it was not as pronounced as in men. Moreover,  
269 the OR gradually increased as MMV decreased in women, while in men, a mild although  
270 not significant rise was detected in Q3 and Q4. Thus, despite gender differences, a trend  
271 toward an increased risk of sarcopenia with decreasing MMV was observed in both men

272 and women.

273 This study revealed specific differences were observed between men and women  
274 regarding the relationship between MMV and sarcopenia. In fact, after full adjustment,  
275 the OR for the lowest quintile (Q1) in men (OR: 6.573) was 3 times higher than that in  
276 women (OR: 2.192). This might be because men and women have different types of  
277 muscle fibers in their MMs. Age-related muscle atrophy occurs preferentially in type II  
278 muscle fibers(29), and it is known that the proportion of type II muscle fibers in the MM  
279 is higher in men than in women(30). Additionally, age-related loss of muscle mass is also  
280 more likely to occur in men(31). Given these factors, it is plausible that MMV serves as  
281 a more sensitive indicator of age-related muscle atrophy in men compared to women.

282 Previous studies have investigated the link between ACTN3 R577X and muscle  
283 mass in older people, but the results have been inconsistent. These discrepancies might  
284 arise from variations in sample sizes or the diverse ages and backgrounds of the  
285 participants. While some studies(19, 32, 33) found that people with the ACTN3 577XX  
286 null genotype were more likely to lose muscle mass, others did not observe this link(34-  
287 36). The present study did not find that ACTN3 R577X was related to ASMM, but it was  
288 notably associated with MMV, particularly in men. The  $\alpha$ -actinin-3 protein, encoded by  
289 *ACTN3*, is specifically expressed in fast-twitch skeletal muscle fibers(14), and the  
290 proportion of type II muscle fibers in MM is higher in men than in women(30). In addition,  
291 the lack of Actn3 leads to a reduction in muscle mass in mice, predominantly in type II  
292 fibers(21), and the muscle mass reduction with age was also enhanced in Actn3-deficient  
293 mice, especially males(37). These findings may explain why there was an association  
294 between MMV and ACTN3R577X in men but not women. The lack of a clear association



295 between ACTN3 R577X and ASMM, in contrast to MMV, may arise because factors such  
296 as BMI strongly influence ASMM, masking potential genetic differences. Similarly, even  
297 though IGF-1 is known to induce skeletal muscle hypertrophy(38), in our study it was  
298 associated with MMV, not ASMM, possibly due to the overriding effect of BMI on  
299 ASMM.

300 This study identified BMI and age as major determinants of ASMM.  
301 Interestingly, however, while the association between BMI and MMV was moderate, that  
302 between age and MMV was not significant. This discrepancy can be attributed to the  
303 functional differences between the two muscle types. ASM contains a higher proportion  
304 of antigravity muscles and is influenced by weight-bearing, whereas MM is primarily  
305 active during mastication. The increased weight-bearing due to a higher BMI can lead to  
306 an increase in ASMM. It is known that high weight-bearing loads predominantly result in  
307 hypertrophy of type II muscle fibers, which are more susceptible to age-related  
308 atrophy(29). In contrast, studies have shown that MM contains a higher percentage of  
309 type I fibers compared to ASM(39). We hypothesize that these differences in fiber type  
310 composition and function might explain why age affects ASM, but not MMV.

311 This study highlights the importance of MMV as a key marker for sarcopenia  
312 risk, particularly among older Japanese men. Since CT and MRI scans of the head are  
313 occasionally performed in the older people, it would be clinically useful to identify  
314 sarcopenia risk by performing an additional MMV analysis. In addition, clinicians should  
315 note the differential impact of BMI and age on ASMM compared to MMV, with the latter  
316 showing no association with age. Additionally, the ACTN3 577X genotype presents a  
317 unique genetic dimension, influencing MMV predominantly in men. Understanding these

318 facts can facilitate more precise early detection of sarcopenia, as well as interventions  
319 tailored to specific gender and genetic profiles.

320 This study has several limitations. Because this cohort included only people  
321 living in urban areas of Japan, our results may not be applicable to people living in other  
322 parts of Japan or in other countries. In addition, since this was a cross-sectional study, we  
323 could not establish any causal relationships. Therefore, further prospective longitudinal  
324 studies are needed to clarify the association between MMV and the development of  
325 sarcopenia. In addition, since we were unable to obtain information on the remaining teeth,  
326 denture status, existence of temporomandibular joint disorder, and bruxism existence of  
327 the participants in this study. Accordingly, recent data suggested that the ACTN3 R557X  
328 polymorphism may influence bruxism in patients with dentofacial deformity(40).  
329 Therefore, further studies addressing these factors are needed.

330 In conclusion, low MMV was a risk factor for sarcopenia, with the effect being  
331 more pronounced in men than in women. While BMI and age were strong determinants  
332 of ASMM, only a weak association was observed between BMI and MMV, with no  
333 correlation between age and MMV. Notably, the IGF-1 level was positively correlated to  
334 MMV, but not ASMM, and the ACTN3 577X genotype linked to reduced MMV in men  
335 but showed no association with ASMM in either sex.

336 **Funding**

337 This study was supported by Strategic Research Foundation at Private Universities  
338 (S1411006) and KAKENHI (18H03184) grants from the Ministry of Education, Culture,  
339 Sports, Science, and Technology of Japan, the Mizuno Sports Promotion Foundation, and  
340 the Mitsui Life Social Welfare Foundation.

341

342 **Acknowledgments**

343 The authors would like to thank all staff for their contributions to data collection at the  
344 Sportology Center.

345

346 **Duality of Interest**

347 The authors have nothing to disclose.

348

349 **Supplemental Figure legends**

350

351 **Figure S1** Flow chart of subject inclusion and exclusion criteria.

352

353 **Figure S2** Steps for the assessment of MMV. All head MRI data are imported into the  
354 workstation software. The masseter muscle is selected and extracted. (a) The color  
355 mapping operation screen is shown. (b) The diaphragm is reconstructed. (c) The volume  
356 is measured.

357

358 **Figure S3** Masseter muscle reconstructed after selective extraction.

359 **(References)**

360

- 361 1. Someya Y, Tamura Y, Kaga H, Nojiri S, Shimada K, Daida H, et al. Skeletal muscle  
362 function and need for long-term care of urban elderly people in Japan (the Bunkyo Health Study):  
363 a prospective cohort study. *BMJ Open*. 2019;9(9):e031584.
- 364 2. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al.  
365 Sarcopenia: European consensus on definition and diagnosis: Report of the European Working  
366 Group on Sarcopenia in Older People. *Age and Ageing*. 2010;39(4):412-23.
- 367 3. Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, et al. Asian Working  
368 Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. *J Am  
369 Med Dir Assoc*. 2020;21(3):300-7.e2.
- 370 4. Sawaya Y, Ishizaka M, Kubo A, Shiba T, Hirose T, Onoda K, et al. The Asian working  
371 group for sarcopenia's new criteria updated in 2019 causing a change in sarcopenia prevalence in  
372 Japanese older adults requiring long-term care/support. *Journal of Physical Therapy Science*.  
373 2020;32(11):742-7.
- 374 5. Ping Liu QH, Shan Hai, Hui Wang, Li Cao and B Dong. Sarcopenia as a predictor of all-  
375 cause mortality among community-dwelling older people: A systematic review and meta-analysis  
376 - *ClinicalKey*. *Maturitas*. 2017;103:16-22.
- 377 6. Wu LC, Kao HH, Chen HJ, Huang PF. Preliminary screening for sarcopenia and related  
378 risk factors among the elderly. *Medicine (Baltimore)*. 2021;100(19):e25946.
- 379 7. Nakanishi S, Iwamoto M, Shinohara H, Iwamoto H, Kaneto H. Significance of body mass  
380 index for diagnosing sarcopenia is equivalent to slow gait speed in Japanese individuals with type  
381 2 diabetes: Cross-sectional study using outpatient clinical data. *J Diabetes Investig*.  
382 2021;12(3):417-24.
- 383 8. Kitamura M, Izawa KP, Ishihara K, Matsuda H, Okamura S, Fujioka K. Physical Activity  
384 and Sarcopenia in Community-Dwelling Older Adults with Long-Term Care Insurance. *European  
385 Journal of Investigation in Health, Psychology and Education*. 2021;11(4):1610-8.
- 386 9. Li W, Yue T, Liu Y. New understanding of the pathogenesis and treatment of stroke-  
387 related sarcopenia. *Biomed Pharmacother*. 2020;131:110721.
- 388 10. González-Fernández M, Perez-Nogueras J, Serrano-Oliver A, Torres-Anoro E, Sanz-  
389 Arque A, Arbones-Mainar JM, et al. Masseter Muscle Thickness Measured by Ultrasound as a  
390 Possible Link with Sarcopenia, Malnutrition and Dependence in Nursing Homes. *Diagnostics*.  
391 2021;11(9):1587.
- 392 11. Sanz-Paris A, González-Fernandez M, Hueso-Del Río LE, Ferrer-Lahuerta E, Monge-  
393 Vazquez A, Losfablos-Callau F, et al. Muscle Thickness and Echogenicity Measured by Ultrasound  
394 Could Detect Local Sarcopenia and Malnutrition in Older Patients Hospitalized for Hip Fracture.  
395 *Nutrients*. 2021;13(7):2401.
- 396 12. Umeki K, Watanabe Y, Hirano H, Edahiro A, Ohara Y, Yoshida H, et al. The relationship

397 between masseter muscle thickness and appendicular skeletal muscle mass in Japanese  
398 community-dwelling elders: A cross-sectional study. *Arch Gerontol Geriatr.* 2018;78:18-22.

399 13. Reis Durão AP, Morosolli A, Brown J, Jacobs R. Masseter muscle measurement  
400 performed by ultrasound: a systematic review. *Dentomaxillofacial Radiology.*  
401 2017;46(6):20170052.

402 14. Miyamoto K, Ishizuka Y, Tanne K. Changes in masseter muscle activity during  
403 orthodontic treatment evaluated by a 24-hour EMG system. *Angle Orthod.* 1996;66(3):223-8.

404 15. Mew JR. The postural basis of malocclusion: a philosophical overview. *Am J Orthod*  
405 *Dentofacial Orthop.* 2004;126(6):729-38.

406 16. Huang Y, Bodnar D, Chen CY, Sanchez-Andrade G, Sanderson M, Biogen Biobank T,  
407 et al. Rare genetic variants impact muscle strength. *Nat Commun.* 2023;14(1):3449.

408 17. Roth SM. Genetic aspects of skeletal muscle strength and mass with relevance to  
409 sarcopenia. *Bonekey Rep.* 2012;1:58.

410 18. Charlier R, Caspers M, Knaeps S, Mertens E, Lambrechts D, Lefevre J, et al. Limited  
411 potential of genetic predisposition scores to predict muscle mass and strength performance in  
412 Flemish Caucasians between 19 and 73 years of age. *Physiol Genomics.* 2017;49(3):160-6.

413 19. Cho J, Lee I, Kang H. ACTN3 Gene and Susceptibility to Sarcopenia and Osteoporotic  
414 Status in Older Korean Adults. *Biomed Res Int.* 2017;2017:4239648.

415 20. Beggs AH, Byers TJ, Knoll JH, Boyce FM, Bruns GA, Kunkel LM. Cloning and  
416 characterization of two human skeletal muscle alpha-actinin genes located on chromosomes 1 and  
417 11. *J Biol Chem.* 1992;267(13):9281-8.

418 21. MacArthur DG, Seto JT, Chan S, Quinlan KG, Raftery JM, Turner N, et al. An Actn3  
419 knockout mouse provides mechanistic insights into the association between alpha-actinin-3  
420 deficiency and human athletic performance. *Hum Mol Genet.* 2008;17(8):1076-86.

421 22. North KN, Yang N, Wattanasirichaigoon D, Mills M, Easteal S, Beggs AH. A common  
422 nonsense mutation results in alpha-actinin-3 deficiency in the general population. *Nat Genet.*  
423 1999;21(4):353-4.

424 23. Kiuchi Y, Makizako H, Nakai Y, Taniguchi Y, Tomioka K, Sato N, et al. Associations of  
425 alpha-actinin-3 genotype with thigh muscle volume and physical performance in older adults with  
426 sarcopenia or pre-sarcopenia. *Exp Gerontol.* 2021;154:111525.

427 24. Abudurezake A, Morita T, Mori T, Amano A. Validity of Diaphragm Volume  
428 Measurements Using Three-Dimensional Computed Tomography. *Juntendo Medical Journal.*  
429 2022;68(5):481-90.

430 25. Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, et al.  
431 International physical activity questionnaire: 12-country reliability and validity. *Med Sci Sports*  
432 *Exerc.* 2003;35(8):1381-95.

433 26. Kobayashi S, Murakami K, Sasaki S, Okubo H, Hirota N, Notsu A, et al. Comparison of  
434 relative validity of food group intakes estimated by comprehensive and brief-type self-

435 administered diet history questionnaires against 16 d dietary records in Japanese adults. *Public*  
436 *Health Nutr.* 2011;14(7):1200-11.

437 27. Brinkman GL, Coates EO, Jr. The effect of bronchitis, smoking, and occupation on  
438 ventilation. *Am Rev Respir Dis.* 1963;87:684-93.

439 28. Roh E, Choi KM. Health Consequences of Sarcopenic Obesity: A Narrative Review.  
440 *Front Endocrinol (Lausanne).* 2020;11:332.

441 29. Ciciliot S, Rossi AC, Dyar KA, Blaauw B, Schiaffino S. Muscle type and fiber type  
442 specificity in muscle wasting. *Int J Biochem Cell Biol.* 2013;45(10):2191-9.

443 30. Tuxen A, Bakke M, Pinholt EM. Comparative data from young men and women on  
444 masseter muscle fibres, function and facial morphology. *Archives of Oral Biology.* 1999;44(6):509-  
445 17.

446 31. Goodpaster BH, Park SW, Harris TB, Kritchevsky SB, Nevitt M, Schwartz AV, et al. The  
447 loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body  
448 composition study. *J Gerontol A Biol Sci Med Sci.* 2006;61(10):1059-64.

449 32. Zempo H, Tanabe K, Murakami H, Iemitsu M, Maeda S, Kuno S. ACTN3 polymorphism  
450 affects thigh muscle area. *Int J Sports Med.* 2010;31(2):138-42.

451 33. Kahraman M, Ozulu Turkmen B, Bahat-Ozturk G, Catikkas NM, Oren MM, Sahin A, et  
452 al. Is there a relationship between ACTN3 R577X gene polymorphism and sarcopenia? *Aging Clin*  
453 *Exp Res.* 2022;34(4):757-65.

454 34. Bustamante-Ara N, Santiago C, Verde Z, Yvert T, Gomez-Gallego F, Rodriguez-Romo  
455 G, et al. ACE and ACTN3 genes and muscle phenotypes in nonagenarians. *Int J Sports Med.*  
456 2010;31(4):221-4.

457 35. San Juan AF, Gomez-Gallego F, Canete S, Santiago C, Perez M, Lucia A. Does complete  
458 deficiency of muscle alpha actinin 3 alter functional capacity in elderly women? A preliminary  
459 report. *Br J Sports Med.* 2006;40(1):e1.

460 36. MacArthur DG, North KN. ACTN3: A genetic influence on muscle function and athletic  
461 performance. *Exerc Sport Sci Rev.* 2007;35(1):30-4.

462 37. Seto JT, Chan S, Turner N, MacArthur DG, Raftery JM, Berman YD, et al. The effect of  
463 alpha-actinin-3 deficiency on muscle aging. *Exp Gerontol.* 2011;46(4):292-302.

464 38. Sartori R, Romanello V, Sandri M. Mechanisms of muscle atrophy and hypertrophy:  
465 implications in health and disease. *Nat Commun.* 2021;12(1):330.

466 39. Sciote JJ, Rowleson AM, Hopper C, Hunt NP. Fibre type classification and myosin  
467 isoforms in the human masseter muscle. *J Neurol Sci.* 1994;126(1):15-24.

468 40. Nicot R, Raoul G, Vieira AR, Ferri J, Sciote JJ. ACTN3 genotype influences masseter  
469 muscle characteristics and self-reported bruxism. *Oral Dis.* 2023;29(1):232-44.

470

Table 1 Characteristics of the study participants.

	All	Men	Women	p value
N	1,484	603	881	
Age (years)	73.0 ± 5.3	72.9 ± 5.3	73.0 ± 5.4	0.716
Masseter muscle volume (ml)	29.2 ± 8.1	35.3 ± 7.8	25.0 ± 5.1	<0.001
Height (cm)	157.9 ± 8.7	165.8 ± 5.9	152.4 ± 5.5	<0.001
Weight (kg)	56.9 ± 10.2	64.6 ± 8.6	51.7 ± 7.6	<0.001
Body mass index (kg/m <sup>2</sup> )	22.7 ± 3.1	23.5 ± 2.8	22.2 ± 3.2	<0.001
Appendicular skeletal muscle mass (kg)	16.2 ± 3.9	20.2 ± 2.6	13.5 ± 1.8	<0.001
Skeletal muscle index (kg/m <sup>2</sup> )	6.4 ± 1.0	7.3 ± 0.6	5.8 ± 0.6	<0.001
Hand grip strength (kg)	25.7 ± 7.0	32.4 ± 5.4	21.2 ± 3.5	<0.001
Total physical activity (Mets*hour/week)	44.2 ± 48.7	48.3 ± 56.8	41.4 ± 42.0	0.007
Low SMI (%)	38.2	30.8	43.2	<0.001
Low hand grip strength (%)	18.7	21.6	16.7	0.018
Sarcopenia (%)	12.0	12.4	11.7	0.664
Energy intake (kcal/day)	1959.6 ± 597.7	2139.7 ± 629.3	1836.3 ± 541.9	<0.001
Protein intake (g/day)	83.0 ± 30.7	83.9 ± 30.4	82.3 ± 30.8	0.325
Brinkman index	246.8 ± 471.9	512.3 ± 594.0	65.1 ± 229.2	<0.001
IGF-1 (ng/mL)	93.4 ± 29.4	98.0 ± 28.8	90.3 ± 29.4	<0.001
Diabetes (%)	11.4	16.6	7.8	<0.001

Data are expressed as mean ± SD. p values are derived from the Student's t-test for continuous variables and the  $\chi^2$  test for non-continuous variables.



Table 2 Characteristics of study participants by MMV quintiles in men (a) and women (b)

(a)

<b>MMV quintile in men (n)</b>	<b>Q1 (120)</b>	<b>Q2 (120)</b>	<b>Q3 (121)</b>	<b>Q4 (121)</b>	<b>Q5 (121)</b>	<b>p value</b>
Mean MMV	25.3 ± 2.8	30.6 ± 1.1	34.5 ± 1.2	39.2 ± 1.4	47.0 ± 4.2	-
(Min~Max) (ml)	(16.2~28.5)	(28.6~32.4)	(32.5~36.7)	(36.8~41.8)	(41.8~59.5)	-
Age (years)	73.8 ± 5.8	73.4 ± 5.6	72.3 ± 5.0	72.5 ± 5.0	72.6 ± 4.9	0.128
Height (cm)	163.8 ± 5.5 <sup>b,c,d</sup>	165.0 ± 5.7 <sup>d</sup>	166.1 ± 5.6	166.4 ± 5.7	167.9 ± 6.5	<0.001
Weight (kg)	61.8 ± 8.2 <sup>c,d</sup>	63.8 ± 8.2 <sup>d</sup>	63.6 ± 7.8 <sup>d</sup>	65.3 ± 8.5 <sup>d</sup>	68.5 ± 8.9	<0.001
Body mass index (kg/m <sup>2</sup> )	23.0 ± 2.7 <sup>d</sup>	23.4 ± 2.7	23.1 ± 2.6 <sup>d</sup>	23.6 ± 2.8	24.3 ± 2.9	<0.001
ASMM (kg)	18.9 ± 2.4 <sup>b,c,d</sup>	19.7 ± 2.4 <sup>d</sup>	20.1 ± 2.2 <sup>d</sup>	20.5 ± 2.6 <sup>d</sup>	21.7 ± 2.6	<0.001
SMI (kg/m <sup>2</sup> )	7.0 ± 0.6 <sup>b,c,d</sup>	7.2 ± 0.6 <sup>d</sup>	7.3 ± 0.5 <sup>d</sup>	7.4 ± 0.6 <sup>d</sup>	7.7 ± 0.6	<0.001
Hand grip strength (kg)	29.7 ± 4.8 <sup>a,d,c,d</sup>	32.0 ± 4.9 <sup>d</sup>	32.2 ± 4.6 <sup>d</sup>	33.5 ± 5.7	34.4 ± 5.7	<0.001
Total PA (Mets*hour/week)	52.8 ± 64.8	41.6 ± 48.6	50.0 ± 50.4	52.4 ± 73.3	44.6 ± 40.5	0.453
Low SMI (%)	48.3	36.7	28.9	27.30	13.20	<0.001
Low hand grip strength (%)	35.0	24.20	19.0	16.5	13.2	<0.001
Sarcopenia (%)	25.0	13.3	9.9	10.7	3.3	<0.001
Energy intake (kcal/day)	2132.9 ± 563.1	2065.1 ± 570.7	2136.1 ± 673.3	2167.8 ± 650.5	2196.0 ± 680.8	0.574
Protein intake (g/day)	86.3 ± 29.5	77.9 ± 25.8	82.0 ± 30.0	85.9 ± 30.9	87.6 ± 34.6	0.086
Brinkman index	544.9 ± 612.5	495.2 ± 596.9	535.8 ± 622.0	484.7 ± 511.1	501.0 ± 627.3	0.917
IGF-1 (ng/mL)	88.5 ± 22.2 <sup>d,c,d</sup>	94.1 ± 29.7 <sup>d</sup>	100.8 ± 27.8	100.4 ± 28.4	105.6 ± 32.2	<0.001
Diabetes (%)	15.8	13.3	16.5	19.0	18.2	0.790



(b)

<b>MMV quintile in women (n)</b>	<b>Q1 (177)</b>	<b>Q2 (176)</b>	<b>Q3 (176)</b>	<b>Q4 (176)</b>	<b>Q5 (176)</b>	<b>p value</b>
Mean MMV	18.5 ± 1.8	22.1 ± 0.8	24.5 ± 0.7	27.4 ± 1.0	32.6 ± 3.2	-
(Min~Max) (ml)	(13.2~20.8)	(20.8~23.4)	(23.4~25.8)	(25.8~29.1)	(29.2~46.3)	
Age (years)	73.5 ± 5.9	72.9 ± 5.6	73.4 ± 5.6	72.8 ± 5.0	72.6 ± 4.8	0.466
Height (cm)	151.7 ± 5.4	152.5 ± 5.6	152.9 ± 6.0	152.3 ± 5.2	152.8 ± 5.5	0.244
Weight (kg)	49.5 ± 7.4 <sup>a,b,d</sup>	52.3 ± 8.5	52.2 ± 7.6	51.2 ± 6.6	53.0 ± 7.3	<0.001
Body mass index (kg/m <sup>2</sup> )	21.6 ± 3.3 <sup>d</sup>	22.5 ± 3.3	22.3 ± 2.9	22.1 ± 2.9	22.8 ± 3.2	0.006
ASMM (kg)	12.9 ± 1.8 <sup>a,b,c,d</sup>	13.5 ± 1.9	13.6 ± 1.9	13.6 ± 1.7	13.9 ± 1.7	<0.001
SMI (kg/m <sup>2</sup> )	5.6 ± 0.6 <sup>a,b,c,d</sup>	5.8 ± 0.6	5.8 ± 0.5	5.8 ± 0.5	6.0 ± 0.5	<0.001
Hand grip strength (kg)	20.2 ± 3.7 <sup>b,c,d</sup>	20.9 ± 3.5 <sup>d</sup>	21.3 ± 3.5	21.8 ± 3.4	22.0 ± 3.2	<0.001
Total PA (Mets*hour/week)	47.2 ± 54.4	37.4 ± 39.6	41.9 ± 42.5	41.1 ± 37.3	39.4 ± 32.8	0.255
Low SMI (%)	58.2	46.0	42.6	39.8	29.5	<0.001
Low hand grip strength (%)	23.7	18.8	17.6	14.2	9.1	0.005
Sarcopenia (%)	18.6	13.1	11.9	8.0	6.8	0.005
Energy intake (kcal/day)	1862.8 ± 588.3	1780.1 ± 545.9	1855.5 ± 506.2	1847.5 ± 518.9	1835.6 ± 548.4	0.625
Protein intake (g/day)	82.1 ± 32.8	79.4 ± 29.0	84.3 ± 29.6	84.5 ± 32.5	81.5 ± 30.3	0.509
Brinkman index	68.8 ± 241.3	100.7 ± 321.5	72.6 ± 230.4	51.3 ± 169.9	32.3 ± 132.8	0.068
IGF-1 (ng/mL)	82.5 ± 22.7 <sup>b,d</sup>	90.4 ± 27.1	94.2 ± 25.2	89.1 ± 23.3	95.2 ± 42.4	<0.001
Diabetes (%)	7.3	9.7	8.0	7.4	6.8	0.882

Abbreviations: MMV, masseter muscle volume; PA, physical activity; ASMM, appendicular skeletal muscle mass; SMI, skeletal muscle index.

p value: one-way ANOVA for continuous variables and  $\chi^2$  test for non-continuous variables

$p < 0.05$ : a vs Q2; b vs Q3; c vs Q4; d vs Q5 for Bonferroni post hoc test.

Table 3 Odds ratios for sarcopenia by MMV quintiles in men (a) and women (b): results of a binomial logistic regression analysis.

(a)

Men						
	Model 1			Model 2		
	OR	95% CI	p value	OR	95% CI	p value
Q5		Reference			Reference	
Q4	3.147	0.967–10.242	0.057	2.985	0.901–9.891	0.074
Q3	2.468	0.747–8.154	0.138	2.395	0.715–8.018	0.157
Q2	3.440	1.078–10.976	0.037	3.007	0.916–9.869	0.069
Q1	6.624	2.175–20.178	<0.001	6.573	2.101–20.559	0.001
Age	1.122	1.066–1.181	<0.001	1.109	1.052–1.170	<0.001
Body mass index	0.708	0.629–0.796	<0.001	0.702	0.622–0.793	<0.001
Total physical activity				0.991	0.983–0.999	0.036
Protein intake				0.993	0.982–1.003	0.188
Brinkman index				1.000	0.999–1.000	0.124
Diabetes				2.272	1.152–4.480	0.018
IGF-1				0.993	0.982–1.004	0.187

(b)

Women						
	Model 1			Model 2		
	OR	95% CI	p value	OR	95% CI	p value
Q5		Reference			Reference	
Q4	0.913	0.396–2.106	0.831	0.910	0.390–2.128	0.829
Q3	1.387	0.635–3.033	0.412	1.381	0.627–3.041	0.424
Q2	1.723	0.797–3.721	0.166	1.621	0.741–3.546	0.227
Q1	2.178	1.044–4.546	0.038	2.192	1.033–4.652	0.041
Age	1.192	1.140–1.247	<0.001	1.195	1.141–1.252	<0.001
Body mass index	0.785	0.723–0.854	<0.001	0.776	0.712–0.845	<0.001
Total physical activity				0.997	0.991–1.002	0.242
Protein intake				0.995	0.988–1.003	0.203
Brinkman index				1.000	0.999–1.001	0.447
Diabetes				2.309	1.164–4.580	0.017
IGF-1				1.001	0.994–1.008	0.812

Data are expressed as odds ratios (OR, 95% CIs). Binomial logistic analysis was performed with age and BMI as covariates for Model 1, and Model 2 added total activity, protein intake, Brinkman index, diabetes, and IGF-1 to Model 1.

Table 4 Characteristics of older participants by ACTN3 R577X genotype.

	Men				Women			
	RR	RX	XX	p value	RR	RX	XX	p value
N	131	298	174		186	461	234	
Age (years)	72.7 ± 5.6	72.8 ± 5.1	73.3 ± 5.3	0.490	73.1 ± 5.6	72.7 ± 5.3	73.6 ± 5.5	0.130
Height (cm)	166.1 ± 5.6	165.8 ± 6.0	165.6 ± 6.1	0.840	152.6 ± 5.8	152.3 ± 5.6	152.6 ± 5.2	0.688
Weight (kg)	65.2 ± 9.4	64.8 ± 8.5	63.8 ± 8.2	0.350	51.3 ± 8.1	51.5 ± 7.3	52.2 ± 7.6	0.399
BMI (kg/m <sup>2</sup> )	24.0 ± 2.8	23.9 ± 2.7	23.6 ± 2.8	0.499	22.4 ± 3.2	22.7 ± 3.2	22.8 ± 3.1	0.415
MMV (ml)	36.4 ± 7.8	35.8 ± 8.0	33.0 ± 7.5 <sup>a</sup>	0.009	25.0 ± 5.1	25.0 ± 5.3	24.9 ± 4.8	0.980
SMI (kg/m <sup>2</sup> )	7.3 ± 0.7	7.4 ± 0.7	7.2 ± 0.6	0.108	5.8 ± 0.6	5.8 ± 0.6	5.8 ± 0.5	0.303
ASMM (kg)	22.0 ± 3.1	22.0 ± 3.0	21.4 ± 2.7	0.097	15.0 ± 2.2	15.1 ± 1.9	15.4 ± 2.1	0.082
Hand grip strength (kg)	32.5 ± 3.3	32.7 ± 5.6	31.7 ± 5.1	0.167	21.4 ± 3.4	21.1 ± 3.7	21.3 ± 3.3	0.562
Total PA (Mets*hour/week)	48.11 ± 74.00	48.81 ± 50.33	47.54 ± 52.33	0.972	39.12 ± 38.04	41.84 ± 42.20	42.29 ± 44.69	0.703
Low SMI (%)	32.6	28.5	33.5	0.467	47.3	43.2	40.2	0.340
Low hand grip strength (%)	9.8	9.1	15.6	0.080	12.9	18.9	15.4	0.151
Sarcopenia (%)	12.9	10.7	15.0	0.391	10.8	11.5	12.0	0.927
Protein intake (g/day)	84.7 ± 28.5	83.7 ± 31.3	83.7 ± 30.4	0.947	81.4 ± 30.6	82.3 ± 30.3	83.2 ± 32.3	0.838
Brinkman index	573.8 ± 598.7	490.3 ± 602.1	503.2 ± 576.2	0.395	84.0 ± 286.5	57.4 ± 202.6	65.4 ± 227.5	0.409
IGF-1 (ng/mL)	96.7 ± 24.7	99.8 ± 30.7	95.8 ± 28.5	0.285	93.4 ± 43.4	91.0 ± 24.0	86.6 ± 24.5	0.052
Diabetes (%)	17.4	18.1	13.3	0.381	5.4	6.9	11.5 <sup>a</sup>	0.039

Data are expressed as mean ± SD.

Abbreviations: MMV, masseter muscle volume; ASMM, appendicular skeletal muscle mass; SMI, skeletal mass index; BMI, body mass index  
p value:  $\chi^2$  test for non-continuous variables. Continuous variables were analyzed by one way ANOVA.  $p < 0.05$ : a vs RR and RX for Bonferroni post hoc test.



Table 5 Association of each factor with MMV or ASMM in a multiple regression model

	Men				Women			
	MMV		ASMM		MMV		ASMM	
	$\beta$	p value	$\beta$	p value	$\beta$	p value	$\beta$	p value
actn3	-0.100	0.011	-0.032	0.280	0.003	0.940	0.058	0.058
Age	-0.047	0.250	-0.296	<0.001	-0.048	0.173	-0.246	<0.001
Body mass index	0.168	<0.001	0.618	<0.001	0.110	0.001	0.600	<0.001
Total physical activity	-0.016	0.685	0.017	0.578	-0.020	0.549	-0.004	0.870
Protein intake	0.044	0.272	0.017	0.581	0.042	0.217	0.048	0.076
Brinkman index	-0.023	0.573	0.002	0.949	-0.072	0.032	-0.019	0.488
Diabetes	0.060	0.134	0.011	0.721	-0.011	0.745	-0.031	0.250
IGF-1	0.173	<0.001	0.028	0.366	0.129	<0.001	0.042	0.128
$R^2$	0.086*		0.474*		0.042*		0.391*	

\*p < 0.001 for analysis of variance

